IgA Nephropathy (IgAN) – Glomerulonephritis Rat Model

An efficient tool for therapeutic testing using the anti-Thy1.1-induced mesangioproliferative glomerulonephritis model.

IgA Nephropathy is the most common primary glomerulonephritis worldwide and remains a major unmet medical need due to limited therapeutic options and variable disease progression. Our anti-Thy1.1-induced mesangioproliferative glomerulonephritis model provides a robust and reproducible platform to investigate the key mechanisms of IgA nephropathy, including mesangial expansion, extracellular matrix deposition, inflammation, and glomerular injury.

Why Choose Our Anti-Thy1.1 IgA Nephropathy Model?

Close Representation of Human Pathology: This model reproduces hallmark features of IgA nephropathy, mesangial cell activation, complement involvement, and glomerular structural alterations; offering a highly relevant tool for preclinical exploration.
Versatile for Therapeutic Development: Whether your goal is to evaluate anti-fibrotic, anti-inflammatory, or immune-modulating strategies, our model supports comprehensive testing of novel therapeutic candidates and mechanism-of-action studies.
High Reproducibility and Robust Readouts: The anti-Thy1.1 induction method ensures consistent disease onset and well-defined kinetics, enabling reliable data interpretation. quantitative histology, biomarker profiling, and functional renal endpoints.
Ethical and Compliant: We adhere to the highest ethical standards and regulatory guidelines in animal research, ensuring the welfare and well-being of our animals at every stage.

Partner with us to accelerate your IgA nephropathy research and drive the development of innovative therapies using our validated anti-Thy1.1 preclinical Model